# Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy

> **NCT02464124** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Sherief Abd-Elsalam** · enrollment: 120 (estimated)

## Conditions studied

- Encephalopathy, Hepatic

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Lactulose

## Key facts

- **NCT ID:** NCT02464124
- **Lead sponsor:** Sherief Abd-Elsalam
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464124, "Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02464124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*